These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31695203)

  • 21. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 22. Vaccines and global health.
    Greenwood B; Salisbury D; Hill AV
    Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2733-42. PubMed ID: 21893534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Vaccination in a developmental perspective].
    Sommerfelt H; Godal T
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2674-7. PubMed ID: 17057768
    [No Abstract]   [Full Text] [Related]  

  • 24. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on the development and use of economic evidence for immunization decision-making in a developing country.
    Molina-Aguilera IB
    Vaccine; 2015 May; 33 Suppl 1():A6-7. PubMed ID: 25919176
    [No Abstract]   [Full Text] [Related]  

  • 26. Global vaccine project gets a shot in the arm.
    Check E
    Nature; 2005 Jan; 433(7024):345. PubMed ID: 15674258
    [No Abstract]   [Full Text] [Related]  

  • 27. New vaccine introduction in the East and Southern African sub-region of the WHO African region in the context of GIVS and MDGs.
    Chauke-Moagi BE; Mumba M
    Vaccine; 2012 Sep; 30 Suppl 3():C3-8. PubMed ID: 22939018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Burden of vaccine-preventable diseases, trends in vaccine coverage and current challenges in the implementation of the expanded program on immunization: A situation analysis of Cameroon.
    Ngwa CH; Doungtsop BK; Bihnwi R; Ngo NV; Yang NM
    Hum Vaccin Immunother; 2022 Dec; 18(1):1939620. PubMed ID: 34197271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maximizing the impact of, and sustaining standing orders protocols for adult immunization in outpatient clinics.
    Tan LJ; VanOss R; Ofstead CL; Wetzler HP
    Am J Infect Control; 2020 Mar; 48(3):290-296. PubMed ID: 31630922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obstacles to developing vaccines for the Third World.
    Robbins A; Freeman P
    Sci Am; 1988 Nov; 259(5):126-33. PubMed ID: 3212439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Financing vaccines for adolescents: a position paper of the society for adolescent health and medicine.
    Kharbanda EO; Lee GM; Koenigs L;
    J Adolesc Health; 2011 Mar; 48(3):320-1. PubMed ID: 21338909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency response vaccines--a challenge for the public sector and the vaccine industry.
    Milstien J; Lambert S
    Vaccine; 2002 Nov; 21(1-2):146-54. PubMed ID: 12443673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introducing new vaccines into developing countries: obstacles, opportunities and complexities.
    Clemens J; Jodar L
    Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges for nationwide vaccine delivery in African countries.
    Songane M
    Int J Health Econ Manag; 2018 Jun; 18(2):197-219. PubMed ID: 29047019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the full public health value of vaccination.
    Gessner BD; Kaslow D; Louis J; Neuzil K; O'Brien KL; Picot V; Pang T; Parashar UD; Saadatian-Elahi M; Nelson CB
    Vaccine; 2017 Nov; 35(46):6255-6263. PubMed ID: 28986035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What can be done to make vaccines more trendy?
    Andre FE
    Expert Rev Vaccines; 2005 Feb; 4(1):23-5. PubMed ID: 15757470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gaps in vaccine financing for underinsured children in the United States.
    Lee GM; Santoli JM; Hannan C; Messonnier ML; Sabin JE; Rusinak D; Gay C; Lett SM; Lieu TA
    JAMA; 2007 Aug; 298(6):638-43. PubMed ID: 17684186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.